

October 12, 2021

National Stock Exchange of India Limited, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India **BSE Limited,** Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India

Dear Sir/Madam,

Subject : <u>Intimation under Regulation 30 of the Securities and Exchange Board of India</u> (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**Stock Code :** <u>BSE – 539787, NSE – HCG</u>

In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information in terms of Regulation 8 of the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, we would like to provide the following updates, for the quarter ended September 30, 2021:

- 1. Post second wave, the Company's operations have returned to regular levels. Our oncology business has grown significantly, showing record revenues on a month on month basis, and we see the growth sustaining in the foreseeable future, as well.
- 2. The Company's regular revenue stream has achieved an all-time high. (i.e., excluding Covid revenue and vaccination revenue).
- 3. The Company continues to generate consistent cash flows led by improved business performance and effective capital allocation.
- 4. The Company acquired oncology hospital labs and clinical trials business from Strand Life Sciences Private Limited ("Strands") for a consideration of INR 808.0 million, and has completed the divestment of its 38.5% stake in Strands for a consideration of INR 1,577.8 million.
- 5. The Company would receive ~INR 1,300 Million in aggregate, upon conversion of warrants to equity by Aceso Company Pte. Ltd., pursuant to the Investment Agreement executed on June 04, 2020; and by Dr. B.S. Ajaikumar, promoter, before the end of the current fiscal year.
- 6. ICRA has upgraded the credit rating of the Company to A plus (stable) from A negative (stable).

## HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489





Kindly take this intimation on record and acknowledge receipt of the same.

Thanking you,

## For HealthCare Global Enterprises Limited

Sunu Manuel Company Secretary & Compliance Officer

## HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489